DRKS00033028Not yet recruitingNot Applicable
Evaluation study of subproject 1 MOVE-COVID-BW (COVID 19)
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- niversitätsklinikum Freiburg
- Enrollment
- 65
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- one to one (—)
- Sex
- All
Inclusion Criteria
- •Only people who have agreed to the MOVE-COVID-VF informed consent form will be included in the study. Inclusion criteria for participation in the study are sufficient knowledge of the German language so that the questionnaires can be completed and an exchange in the context of qualitative interviews is possible. Participation in the interviews with socially disadvantaged parents is only possible if they take part in the questionnaire survey and are invited to an interview at the end of the questionnaire by calculating their social status.
Exclusion Criteria
- •not applicable
Investigators
Similar Trials
Completed
Not Applicable
A Study on the efficacy of BVVR001 (development code)JPRN-UMIN000027751Kao Corporation25
Completed
Unknown
'The MOVE' pilot study: Short physical activity breaks during ordinary lectures in upper secondary school; A 12 week pilot studyShort physical activity breaks led by pupils during ordinary lectures in upper secondary schoolISRCTN10405415Inland Norway University of Applied Sciences494
Active, not recruiting
Not Applicable
'The MOVE'-study: Short physical activity breaks during ordinary lectures in upper secondary school; A 25-week randomised controlled trial.Short physical activity breaks led by pupils during ordinary lectures in upper secondary schoolNot SpecifiedISRCTN11783541Inland Norway University of Applied Sciences510
Completed
Not Applicable
PostCovidCare - Pilot Study on the Implementation of a Post-COVID-19 Case-management with browser-based symptom diary in general practice.Post COVIDDRKS00029951niversitätsklinikum Heidelberg33
Completed
Phase 2
A phase II study to evaluate the effect on the combination chemotherapy of CPT-11 and S-1 for advanced/recurrent colon cancer which combines genetic analysis on adverse events (OGSG 0405)Patients with advanced and/or recurrent colon cancerJPRN-UMIN000000855OGSG30